Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Abstract: An automatic transaction apparatus includes a card insert port into which a card medium is inserted; a paper medium discharge section that has a discharge port from which a paper medium is discharged; and a conveying path that has a lower guide surface and an upper guide surface that guide conveyance of the paper medium and discharge of the paper medium from the discharge port, a dimension of the conveying path in a thickness direction of the paper medium being smaller than a thickness of the card medium at least at one position of the conveying path along a conveying direction.

Abstract: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin.

Abstract: Disclosed is a salt and crystal of a 2-(oxazole-2-yl)phenol derivative which are the intermediate in the process of producing a N-phenyl-N?-phenylsulfonyl piperazine derivative. Further disclosed is a method of producing the salt and the crystal of the compound represented by Formula(I): wherein X is halogen; as well as a process of producing N-phenyl-N?-phenylsulfonyl piperazine derivative through the salt.

Abstract: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin.

Abstract: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin.

Abstract: Disclosed is a process for producing a pyrazole carboxylic acid derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. A compound represented by the Formula (XI): is useful as a significant intermediate of an 11?HSD-1 inhibitor, wherein R1 and R2 are each independently hydrogen or substituted or unsubstituted alkyl, R3 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocyclyl and R4 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocyclyl.

Abstract: An automatic transaction apparatus includes a card insert port into which a card medium is inserted; a paper medium discharge section that has a discharge port from which a paper medium is discharged; and a conveying path that has a lower guide surface and an upper guide surface that guide conveyance of the paper medium and discharge of the paper medium from the discharge port, a dimension of the conveying path in a thickness direction of the paper medium being smaller than a thickness of the card medium at least at one position of the conveying path along a conveying direction.

Abstract: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin.

Abstract: Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); [wherein R1, R2, R2?, R3 and R3? independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N—R11 or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

Abstract: The present invention includes a first-language basic input/output control program linked with a first-language OS an a computer and an input/output device for executing first-language application software in object code form, an emulator linked with second-language application software, the first-language basic input/output control program and the first-language OS for executing the second-language application software in object code form and a way of activating and terminating the emulator. Thereby, there is provided a computer system which permits the first-language application software and the second-language application software to be operated using the identical computer, input/output device and first-language OS.